Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage
NCT:NCT05103566 · RECRUITING
广告
NCT编号NCT05103566
状态RECRUITING
开始日期2022-10-04
SponsorMassachusetts General Hospital (OTHER)
First posted
Last updated
简要摘要
This is a single-site, single-arm, open-label pilot study assessing the safety, feasibility, and efficacy of non-invasive vagus nerve stimulation (nVNS), gammaCore, for the acute treatment of aneurysmal subarachnoid hemorrhage (SAH) subjects in a neurocritical care setting. 25 patients will be enrolled, all treated with an active device. The primary efficacy outcomes are reduced aneurysm rupture rate, reduced seizure and seizure-spectrum activity, minimized hemorrhage grades, and increased survival.
官方来源
在 ClinicalTrials.gov 上查看 →数据来自 ClinicalTrials.gov API。有关最新状态,请参阅官方记录。